Molecular Diagnostics in Colorectal Cancer

Ys, Rustam Effendi; Rey, Imelda

doi:10.24871/161201526-33

InaJGHE

2015

DOI: 10.24871/161201526-33

|View full text |Cite

Molecular Diagnostics in Colorectal Cancer

Rustam Effendi Ys

Imelda Rey

Abstract: Colorectal cancer (CRC) presents in one of three patterns: sporadic colorectal cancer in those without a family history (65-85%); those with a family history (familial CRC) 10-25% of cases; inherited CRC accounting for less of 10% cases and presents as well-characterized cancer predisposition syndromes including

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Book1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Biomarkers as a Therapeutic Approach in Colorectal Carcinoma

Effendi-YS,

Rey,

Rey

2024

Advances in Diagnosis and Therapy of Colorectal Carcinoma

Self Cite

View full text Add to dashboard Cite

This review highlights the most promising biomarker tests of tumor tissue from colonoscopy biopsy for more individualized therapeutic approaches to patients with colorectal carcinoma (CRC). Biomarkers are a key tool in early detection, survival, and predicting treatment response and prognostic value. The tests can help doctors to select a specific CRC treatment and targeted therapy. CRC is the third most common cancer diagnosed, and the second leading cause of cancer-related deaths worldwide, despite the progress made in detection and management through surgery, chemotherapy, radiotherapy, and immunotherapy. With a population totaling 273,523,621 people, Indonesia has estimated 396,914 new cases of all cancer and 234,511 cancer-related deaths. Among those cancer cases, estimated 34,189 new CRC cases and 17,786 CRC deaths occurred in 2020. Most of CRC cases were located in the rectum compared to those in the distal colon or proximal colon. CRC is a heterogeneous cancer. Its therapeutic approaches vary, depending on the tumor location (proximal, distal colon, or rectum), clinical signs and symptoms, staging and biomarkers such as KRAS and NRAS, BRAF V600E, MSI high (dMMR), CIN, HER2-amplified, PD-1, CTLA-4, MEK, and NTRK gene fusion-positive. CSCs and other biomarkers are being developed and remain under investigation.

show abstract

Biomarkers as a Therapeutic Approach in Colorectal Carcinoma

Effendi-YS,

Rey,

Rey

2024

Advances in Diagnosis and Therapy of Colorectal Carcinoma

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Molecular Diagnostics in Colorectal Cancer

Cited by 1 publication

References 15 publications

Biomarkers as a Therapeutic Approach in Colorectal Carcinoma

Biomarkers as a Therapeutic Approach in Colorectal Carcinoma

Contact Info

Product

Resources

About